Navigation Links
EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million

    ATHENS, Greece, August 6 /PRNewswire/ --

    - Not for Release, Publication or Distribution Directly or Indirectly in
      or Into the United States, Canada, Australia, South Africa or Japan or
      any Other Jurisdiction in Which Such Publication or Distribution Would
      be Unlawful

    - This Announcement is not a Prospectus and is not an Offer to Sell or a
      Solicitation of any Offer to buy any Securities in the United States or
      in any Other Jurisdiction

Alapis S.A. ("Alapis" or "the Company") announces that, on 5 August, 2009, the Company's Board of Directors approved a share capital increase by way of pre-emptive rights for existing shareholders that will increase the Company's share capital by EUR 294,180,066.

The share capital increase will be effected through the issue of 980,600,220 new ordinary shares of a nominal value EUR0.30 each, with payment in cash.

Shareholders of Alapis will be entitled to one subscription right for each existing share held. The exercise of one subscription right will entitle the holder to subscribe for one new share at the proposed subscription price of EUR 0.46 per new share. In addition, those who will exercise their subscription rights will be entitled to subscribe for a number of additional new shares at the subscription price (oversubscription rights). The total gross proceeds will amount to approximately EUR 451.1 million.

The Company intends to use the net proceeds from the share capital increase to repay part of its existing short-term debt, finance expected working capital requirements and pursue targeted acquisitions of companies and other assets, in order to further support its growth strategy in the Greek and South-Eastern European healthcare markets.

Alapis has been informed that Lamda Partners L.P., a private equity fund, has irrevocably undertaken to participate in the share capital increase through one or more of its wholly owned subsidiaries by investing approximately EUR 90.2 million through the exercise of 196,120,044 rights, representing 20% of the new ordinary shares. Such rights will be acquired from Dr. Lavrentis Lavrentiadis or in the open market. The Company was also informed that Dr.Lavrentiadis is a director of the general partner of Lamda Partners L.P.

A syndicate of international firms composed of ABN AMRO, BofA Merrill Lynch, BNP PARIBAS, Deutsche Bank AG London Branch and Jefferies has agreed to subscribe or procure subscribers for any new shares which may remain unsubscribed at the end of the subscription period, subject to customary terms and conditions.

The Company's prospectus that will be prepared in relation to the share capital increase will be subject to approval by the Hellenic Capital Market Commission.

The Company will endeavour to complete the capital increase by the end of September, subject to obtaining all regulatory and other approvals in a Timely manner.

The decision of the Board of Directors is pursuant to the authority given to it by the second repeat Extraordinary General Meeting of Alapis' shareholders held on 29 September 2008.

    Further inquiry note:

    Norbert Schmidt-Gollas
    Aftokratoros Nikolaou str., No 2,
    p.c.176 71 Athens
    tel. +30-213-0175000-1
    fax +30-210-9238460

    emitter:         ALAPIS S.A.
                     Aftokratoros Nikalaou str. 2
                     17671 Athen
    phone:           +30-213-0175000-1
    FAX:             +30-210-923-8460
    sector:          Pharmaceuticals
    ISIN:            GRS322003013

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Innovaacom, a leading provider of ... a survey of educational needs for pharmacists worldwide. The poll of pharmacists in ... high quality online and face-to-face education for pharmacists who are fast becoming the ...
(Date:11/30/2015)... ... 30, 2015 , ... Several significant coding-related changes are anticipated ... to include new codes for spine and hip X-rays, paravertebral facet blocks and ... code changes in musculoskeletal, radiology and nervous system sections on an Orthopedic practice. ...
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ideas ... Sublime Beauty NATURALS®. All products are available on Amazon or its webstore. , ... facial serums and USDA Certified Organic Sesame Oil for Oil Pulling," says Kathy ...
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... NewsWatch featured ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... be a reality in the future. , It’s the future because flying cars are ...
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog Distortion ... tool designed specially for Final Cut Pro X. FCPX users can ... easy-to-use modification controls. Destoying and creating chaotic distortion is now quick and simple, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Japanese therapeutic drug monitoring market, including ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology: